EUCTR2020-005566-33-FR进行中（未招募）1 期
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 690
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •-Aged 18 years up to 60 years on the day of inclusion
- •-A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- •Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.
- •Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on Day 1 and the test will be repeated on D29 to confirm the participant is still not pregnant within 28 days of vaccine administration.
- •-Informed consent form has been signed and dated
- •-Able to attend all scheduled visits and to comply with all study procedures
- •For participants enrolled in Asian countries as part of the additional cohort only: know Chinese origin, defined as having at least one biological parent of Chinese origin, and will be self-reported by the participant
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 690
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •. Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the first 2 years of the 5-year follow-up in another clinical study investigating a vaccine, drug, medical device, or medical procedure. Enrollment in another study after the first 2 years is permitted, assuming that it does not exclude participation in this study.
- •. Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination (prior to visit 4), except for influenza vaccination, which may be received at least 2 weeks before study vaccines. This exception includes all influenza vaccines including monovalent pandemic influenza vaccines.
- •. Previous vaccination against a FV disease at any time including YF with either the study vaccine or another vaccine.
- •. Receipt of immune globulins, blood, or blood-derived products in the past 6 months.
- •. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy, or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •. Known history of any FV infection.
- •. Known systemic hypersensitivity to any of the vaccine components, eggs, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.
- •. Known history or laboratory evidence of HIV infection.
- •. Known history or laboratory evidence of hepatitis B or hepatitis C infection.
- •. Personal or family history of thymic pathology (thymoma, thymectomy, or myasthenia).
- •. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- •. Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
- •. Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion, including malignancy, such as leukemia, or lymphoma.
- •. Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature = 100.4°F or 38°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- •. Administration of any anti-viral within 2 months preceding the vaccination and planned administration up to the 6 weeks following the vaccination.
- •. Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
- •. Planned travel in a YF endemic country within 6 months of investigational or control vaccine administration.
研究者
相似试验
进行中（未招募）
1 期
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and AsiaMedDRA version: 20.0Level: PTClassification code: 10048240Term: Yellow fever Class: 100000004862Yellow feverCTIS2022-502047-35-00Sanofi Pasteur690
进行中（未招募）
1 期
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and AsiaEUCTR2020-005566-33-DESanofi Pasteur690
进行中（未招募）
1 期
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and AsiaPrevention of yellow feverMedDRA version: 20.0Level: PTClassification code 10048240Term: Yellow feverSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005566-33-FISanofi Pasteur690
进行中（未招募）
1 期
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and AsiaEUCTR2020-005566-33-ESSanofi Pasteur690
进行中（未招募）
不适用
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and ChildreJapanese EncephalitisEUCTR2015-005193-38-Outside-EU/EEASanofi Pasteur SA300